CagriSema in Singapore: The New Combination Weight-Loss Injection Explained

CagriSema is one of the most talked-about names in weight-loss medicine, and for good reason. It is the first drug to combine two different appetite hormones in a single weekly injection, and its trial results sit among the highest ever reported. For people in Singapore following this space, the questions are simple: what is it, how well does it work, and can you get it here?

This guide answers those questions with current, accurate information. It explains what CagriSema is, how the two-drug approach works, what the trials actually showed, how it compares to the injections already in use, and the honest position on its availability in Singapore today.

What Is CagriSema?

CagriSema is a once-weekly injectable medication for weight management, developed by Novo Nordisk, the company behind Wegovy and Ozempic. It is a fixed-dose combination, meaning two active medicines are delivered together in a single shot: Semaglutide 2.4 mg and Cagrilintide 2.4 mg.

What makes it notable is that it is the first medicine to pair a GLP-1 receptor agonist with an amylin analogue for weight loss. Each drug works on a different appetite pathway, and the idea is that hitting two systems at once produces a stronger effect than either alone. You can read more about the amylin half of the pairing in our guide to Cagrilintide in Singapore.

How Does CagriSema Work?

CagriSema combines two complementary mechanisms. Semaglutide is a GLP-1 receptor agonist, the same active ingredient found in Wegovy. It mimics the GLP-1 hormone, which reduces appetite and slows how quickly the stomach empties. Cagrilintide is an amylin analogue. It mimics amylin, a separate hormone released after eating that also signals fullness to the brain.

By acting on the GLP-1 system and the amylin system together, CagriSema targets two appetite pathways rather than one. For suitable patients, combined with a reduced-calorie diet and more physical activity, this leads to reduced hunger and more consistent weight loss than a single-pathway drug tends to achieve.

How Effective Is CagriSema for Weight Loss?

The results come from Novo Nordisk’s large Phase 3 REDEFINE programme. In the pivotal REDEFINE 1 trial, adults with obesity, or overweight with a weight-related condition, lost an average of 22.7% of their body weight over 68 weeks, compared with about 16% for Semaglutide alone in the same trial. Roughly one in three participants lost 25% or more.

That places CagriSema among the most effective weight-loss medicines studied to date. It is worth being straight about one nuance, though. In a separate head-to-head trial called REDEFINE 4, CagriSema produced around 23% weight loss against Tirzepatide’s 25.5%, so it did not beat the strongest single injectable on that measure. The headline remains strong: this is a very high level of weight loss, and higher-dose versions are still being tested.

How does CagriSema compare to Wegovy and Mounjaro?

There are now several routes to GLP-1 based weight loss, so the comparison matters.

• Versus Wegovy. Wegovy contains Semaglutide alone. CagriSema contains that same Semaglutide plus Cagrilintide, and in trials it delivered clearly more weight loss than Semaglutide by itself, around 22.7% against 16%.
• Versus Mounjaro. Mounjaro (Tirzepatide) remains the benchmark single injectable. In the one head-to-head trial, Tirzepatide edged ahead at 25.5% against CagriSema’s 23%, so the two are broadly in the same top tier.

The practical takeaway is that CagriSema is a genuine top-tier option, competitive with the strongest treatments available, with the distinction of being the first to use the dual GLP-1 and amylin approach.

What Are the Side Effects of CagriSema?

Because it works like the other injectable weight-loss medicines, CagriSema shares their side-effect profile. In the REDEFINE trials the most common effects were gastrointestinal and included nausea, constipation, and vomiting. These were mainly mild to moderate, tended to be strongest when starting or increasing the dose, and generally eased over time.

Discontinuation due to side effects was low, at roughly 6% of participants. As with any weight-management medication, CagriSema is not suitable for everyone, and it is designed to be used under medical supervision alongside diet and activity changes. A proper medical assessment is what determines whether this class of drug is appropriate for a given person, which is one reason these treatments are prescription-only.

Is CagriSema Available in Singapore?

Not yet. This is the important part to be clear about. As of mid-2026, CagriSema has not been approved by regulators anywhere and remains an investigational medicine outside clinical trials.

Novo Nordisk filed its application with the US FDA in December 2025, based on the REDEFINE 1 and REDEFINE 2 trials, and an FDA decision is anticipated by late 2026. It is not approved in the US or the EU, and it has not been registered with Singapore’s Health Sciences Authority. Until the HSA reviews and clears it, CagriSema cannot be legally prescribed or sold in Singapore. Any product marketed here now under the name CagriSema should be treated as a warning sign, since unapproved injectables bought online can be counterfeit, contaminated, or wrongly dosed.

The reassuring news is that effective, HSA-approved weight-loss options already exist here. Wegovy and Mounjaro are available through licensed providers, so medically supervised weight management does not depend on waiting for CagriSema.

What Should You Do if You Are Interested in CagriSema?

If the combination approach interests you, the sensible step is not to chase an unapproved product, but to speak with a doctor about what is available and suitable for you today. A licensed physician can assess whether you are a candidate for medical weight management, start you on an approved treatment if appropriate, and keep you informed as new options like CagriSema move through regulatory review. Being already under proper medical care makes it straightforward to discuss or switch treatments when the landscape changes.

Speak with a Doctor Online

Sire is a men’s health telemedicine platform in Singapore. If you are considering medically supervised weight management, a licensed doctor can assess your suitability for an approved treatment and keep you updated as newer options like CagriSema become available. Start a weight management consultation or explore our other men’s health services.